A gene called TGFB2 is linked to worse survival in glioma
Original title: TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
Researchers only looked back at tumor samples from patients. No treatment was tested.
The short version
Gliomas with high levels of a gene called TGFB2 tend to grow in a way that holds back the immune system, and patients with high levels did not live as long.
What was studied. Researchers looked at tumor data already collected from people with diffuse glioma: A glioma whose cells spread out into the brain around it instead of staying in one lump. That is why the edge on a scan is not a clean line. See the glossary. They used one group of 667 patients to find patterns, then checked those patterns in a second group of 404 patients.
What they found. Tumors had more TGFB2 activity than normal brain tissue. Levels were highest in glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. In the first group, patients with high TGFB2 lived 648 days, compared with 2907 days for patients with low levels. In the second group it was 863 days compared with 3107 days. Tumors with high TGFB2 also had more immune cells of a type that can shut down the body's attack on cancer.
What this means, and what it doesn't
What it could mean: TGFB2 may turn out to be a useful marker. A test for it could one day help doctors sort patients into groups, or help pick who might be tried on drugs that target TGFB2 or the immune system. Right now it does not change any treatment you can get.
What it doesn't mean: This is not a new treatment, and it is not a cure. Nobody in this study was given a drug. Researchers only looked back at tumor samples and records that had already been collected. It does not mean lowering TGFB2 would help you live longer. That has not been tested in people. The authors are suggesting it be studied in future trials, which would take years.
Source: PubMed, June 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.